Navigation Links
Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
Date:8/25/2010

WALTHAM, Mass., Aug. 25  /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's Depakote/Abbott's Depakote ER, generics), combined with projected generic erosion of the atypical antipsychotic drug class will cause a precipitous $2.3 billion decline in the bipolar disorder drug market over the next decade.

The Pharmacor 2010 findings from the topic entitled Bipolar Disorder reveal that although patient share for atypical antipsychotics will increase through 2019, particularly in France, Germany, Italy, Spain, the United Kingdom and Japan, sales of atypical antipsychotics will decline significantly over the forecast period owing to the generic erosion of key agents such as AstraZeneca/Astellas's Seroquel/AstraZeneca's Seroquel XR, Eli Lilly's Zyprexa, Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify and Pfizer's Geodon.

The Pharmacor 2010 findings reveal that bipolar depression is the largest unmet need in bipolar disorder, as experts consistently indicate that few therapies achieve sufficient efficacy in this market segment. Two emerging atypical antipsychotics will likely gain approval for bipolar depression: Forest Laboratories/Gedeon Richter/Mitsubishi Pharma's cariprazine and Dainippon Sumitomo Pharma/Sepracor's (soon to be Sunovion Pharmaceuticals) lurasidone. Lurasidone, which is expected to gain approval for bipolar depression in 2012, will become a market leader in 2019.

"The bipolar depression market segment represents the greatest commercial opportunity and we expect that lurasidone will gain approval for bipolar depression in 2012, following its launch in 2011 for the treatment of schizophrenia," said Decision Resources Analyst Alana Simorellis, Ph.D. "Dainippon Sumitomo Pharma and Sepracor will differentiate lurasidone based on its efficacy in bipolar depression, as well as its potential for efficacy in cognitive symptoms, and its relatively mild weight gain profile compared with currently marketed atypical antipsychotics. As a result, we forecast lurasidone to garner peak year sales in the range of $500 million to $1 billion."

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

CONTACT:

Decision Resources, Inc.

Lisa Osgood

+1-781-296-2606

losgood@hl-isy.com


'/>"/>
SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel to Raise $9.4 Million Through Registered Direct Offering
2. Managed Care Pull-Through Initiatives Suffer from Poor Measurement of ROI
3. Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ)
4. Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
5. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
6. Arizona Residents Get Help With Medicines Through PPA 2.0
7. Gaining Visibility and Control Over Purchases of Medical Devices is the Focus of a GHX Presentation at Premier Annual Breakthroughs Conference and Exhibition
8. NanoPowers Raises CHF 5 Million ($4.5 Million) in Series A Financing to Support Development of Breakthrough Urinary Incontinence Device
9. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
10. RunE2E and Freudenberg IT Create Customer Value Through Implementation of SAP® CRM in Hosted, Private Cloud
11. Hothead Technologies Partners with Shafer Enterprises to Provide Break-Through Technology to Monitor and Manage Normothermia in Medical Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23. Januar 2017  ResMed (NYSE: RMD ... 3B Medical ( Winter Haven, Florida ) ... über die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ... 3B leisten, um das in Florida ...
(Date:1/23/2017)... Jan. 23, 2017 Just two weeks remain until legal experts ... gather in Central London to discuss the flow ... in the market, Parallel Trade 2017 . In the ... of attendees which is available to read in the event download ... Some of ...
(Date:1/21/2017)... According to a new market research report "Life Science ... Component (Software, Service), Delivery (On premise, Cloud), End user (Pharmaceutical, Biotechnology, ... market is expected to reach USD 24.73 Billion by 2021 from ... the forecast period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:1/23/2017)... Portland, Oregon (PRWEB) , ... January 23, 2017 ... ... systems, announced today it has earned organic certification under the USDA National Organic ... the USDA Organic Certification process, we have established organic production and handling systems ...
(Date:1/23/2017)... ... ... “The Inn at the Mill”: a story of love and redemption, hope and uncertainty ... and content. , “The Inn at the Mill” is the creation of published author, ... and is now living in Berks County on Crow Hill. The inn, the ...
(Date:1/23/2017)... Georgia (PRWEB) , ... January 23, 2017 , ... Valentine’s Day is a time when ... their loved ones. For those who may be looking for the ideal present, Atlanta-based ... certificate and get an additional $25 free. Or, spend $200 and get $50 free. ...
(Date:1/21/2017)... FL (PRWEB) , ... January 21, 2017 , ... Caronlab ... recently attended the January ECRM Trade Show in Hilton Head, SC, where it benefited ... reputation for the quality of its beauty and wellness products. At this trade show, ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting ... family, friends, and community. “Coming Home 2017” will be held on Friday ...
Breaking Medicine News(10 mins):